Immunological findings supporting intralymphatic treatment with Diamyd® to be presented today at a diabetes meeting in Stockholm

A new analysis of results from the DIAGNODE-1 trial that supports the association between immunological and clinical response following intralymphatic administration of Diamyd® will be presented today at the Scandinavian Society for Study of Diabetes meeting in Stockholm.The immunlogical findings are in alignment with previously announced results from DIAGNODE-1, showing that antigen-specific increase in the secretion of the cytokine IL-10, decreased cell proliferation and activation of GAD65-specific T-lymphocytes as well as an altered antibody response to GAD65, associate with clinical